Aytu Biopharma (AYTU) Total Non-Current Liabilities (2015 - 2026)
Aytu Biopharma (AYTU) posted quarterly Total Non-Current Liabilities of $16.6 million for Q1 2026, down 10.88% year-over-year from $18.6 million in Q1 2025, and down 60.76% quarter-over-quarter from $42.2 million in Q4 2025.
Aytu Biopharma (AYTU) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Total Non-Current Liabilities for 12 consecutive years, with $16.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 10.88% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (down 10.88% YoY), while the FY2025 annual figure was $42.1 million, up 49.72% from the prior year.
- Total Non-Current Liabilities declined to $16.6 million in Q1 2026 per AYTU's latest filing, from $42.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $104.7 million in Q1 2023 and bottomed at $14.4 million in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $51.1 million across 5 years, with a median of $35.8 million in 2025.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities sank 86.25% — and 2025, when it jumped 97.24%.
- Aytu Biopharma's Total Non-Current Liabilities stood at $85.8 million in 2022, then slumped by 60.15% to $34.2 million in 2023, then tumbled by 37.4% to $21.4 million in 2024, then jumped by 97.24% to $42.2 million in 2025, then plunged by 60.76% to $16.6 million in 2026.
- Business Quant data shows AYTU's Total Non-Current Liabilities at $16.6 million in Q1 2026, $42.2 million in Q4 2025, and $35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Aytu Biopharma | 24.70 Mn | -2.01 Mn | 7.60 Mn | 16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.57 Mn |
| Dec 31, 2025 | 42.24 Mn |
| Sep 30, 2025 | 35.82 Mn |
| Jun 30, 2025 | 42.15 Mn |
| Mar 31, 2025 | 18.60 Mn |
| Dec 31, 2024 | 21.41 Mn |
| Sep 30, 2024 | 24.75 Mn |
| Jun 30, 2024 | 28.15 Mn |
| Mar 31, 2024 | 14.40 Mn |
| Dec 31, 2023 | 34.21 Mn |
| Sep 30, 2023 | 92.62 Mn |
| Jun 30, 2023 | 28.09 Mn |
| Mar 31, 2023 | 104.72 Mn |
| Dec 31, 2022 | 85.84 Mn |
| Sep 30, 2022 | 96.09 Mn |
| Jun 30, 2022 | 80.52 Mn |
| Mar 31, 2022 | 102.11 Mn |
| Dec 31, 2021 | 117.73 Mn |
| Sep 30, 2021 | 115.91 Mn |
| Jun 30, 2021 | 109.62 Mn |